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José Campos2,3 and Jesús Oteo2,3* on behalf of the Spanish Antibiotic Resistance Surveillance Programme
Collaborating Group†
1Servicio de Microbiologı́a del Hospital Universitario de Getafe, Getafe, Madrid, Spain; 2Laboratorio de Referencia e Investigación en
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Objectives: There is little information about carbapenemase-producing (CP) Citrobacter spp. We studied the mo-
lecular epidemiology and microbiological features of CP Citrobacter spp. isolates collected in Spain (2013–15).
Methods: In total, 119 isolates suspected of being CP by the EUCAST screening cut-off values were analysed.
Carbapenemases and ESBLs were characterized using PCR and sequencing. The genetic relationship among
Citrobacter freundii isolates was studied by PFGE.
Results: Of the 119 isolates, 63 (52.9%) produced carbapenemases, of which 37 (58.7%) produced VIM-1,
20 (31.7%) produced OXA-48, 12 (19%) produced KPC-2, 2 (3.2%) produced NDM-1 and 1 (1.6%) produced VIM-
2; 9 C. freundii isolates co-produced VIM-1 plus OXA-48. Fourteen isolates (22.2%) also carried ESBLs: 8 CTX-M-9
plus SHV-12, 2 CTX-M-9, 2 SHV-12 and 2 CTX-M-15. Fifty-seven isolates (90.5%) were C. freundii, 4 (6.3%) were
Citrobacter koseri, 1 (1.6%) was Citrobacter amalonaticus and 1 (1.6%) was Citrobacter braakii. By EUCAST break-
points, eight (12.7%) of the CP isolates were susceptible to the four carbapenems tested. In the 53 CP C. freundii
analysed by PFGE, a total of 44 different band patterns were observed. Four PFGE clusters were identified: cluster
1 included eight isolates co-producing VIM-1 and OXA-48; blaVIM-1 was carried in a class 1 integron (intI–blaVIM-1–
aacA4–dfrB1–aadA1–catB2–qacED1/sul1) and blaOXA-48 was carried in a Tn1999.2 transposon.
Conclusions: We observed the clonal and polyclonal spread of CP Citrobacter spp. across several Spanish geo-
graphical areas. Four species of Citrobacter spp. produced up to five carbapenemase types, including co-
production of VIM-1 plus OXA-48. Some CP Citrobacter spp. isolates were susceptible to the four carbapenems
tested, a finding with potential clinical implications.
Introduction
The unceasing increase in infections due to carbapenemase-
producing (CP) Enterobacteriaceae (CPE) is one of the most worry-
ing threats to the health services worldwide. Frequently, patients
with CPE infections cannot be treated with effective antibiotics be-
cause of the dearth of alternative drugs.1,2 Thus far, the main clin-
ical load of CPE has been due to the increasing incidence of
nosocomial infections caused by Klebsiella pneumoniae, but other
CP species, such as Escherichia coli, Enterobacter spp. and Serratia
marcescens, have also been detected in nosocomial settings.3,4
Citrobacter spp., mainly Citrobacter freundii, have been
recognized as opportunistic pathogens responsible for healthcare-
associated infections such as urinary and respiratory tract infec-
tions. However, little information is available about CP Citrobacter
spp.; very few studies have reported C. freundii producing VIM or
KPC.4–8 Some Enterobacteriaceae species, such as Citrobacter spp.
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or Enterobacter spp., often present decreased susceptibility to car-
bapenems, mainly ertapenem, due to the overproduction of
chromosomal AmpC b-lactamase plus reduced outer membrane
permeability;9 as a consequence, production of carbapenemases
in these species may be underdiagnosed in clinical microbiology
laboratories.
The aim of this study was to gain insight into the microbiological
features and molecular epidemiology of CP Citrobacter spp., mainly
C. freundii, submitted to the Spanish National Reference Centre of
Microbiology from 2013 to 2015.
Materials and methods
This study was performed by the unrestricted and non-mandatory national
Spanish Antibiotic Resistance Surveillance Programme operated by our
official public health institute (Instituto de Salud Carlos III). When this non-
mandatory programme was launched in 2009, all Spanish clinical micro-
biology laboratories and health-associated professionals were personally
contacted and encouraged to submit their carbapenem-resistant
Enterobacteriaceae to our antibiotic reference laboratory for molecular and
epidemiological characterization. From January 2013 to December 2015, a
total of 115 public hospitals (about 35% of the total Spanish public hos-
pitals) participated in the programme. In this study we included all
Citrobacter spp. isolates submitted to our reference laboratory from 2013 to
2015 suspected of being carbapenemase producers according to the
EUCAST screening cut-off values for CPE.10 Only the first isolate per patient
was analysed. Isolate identification was performed using MALDI-TOF MS
(Bruker Daltonik GmbH, Leipzig, Germany).
Antibiotic susceptibility testing was performed by microdilution
(MicroScan, Beckman Coulter, Inc.) and interpreted according to EUCAST
breakpoints.10,11 According to EUCAST recommendations, inhibition of car-
bapenemase activity was determined by using EDTA, phenyl-boronic acid
and cloxacillin. In addition, all the isolates were tested with both the Carba
NP method12 and the modified Hodge test13 with a meropenem disc con-
taining 600 mg of cloxacillin.
The presence of genes encoding carbapenemases (blaOXA-48, blaKPC,
blaVIM, blaIMP and blaNDM) and ESBLs (blaCTX-M, blaSHV and blaTEM) was deter-
mined by PCR and DNA sequencing.14,15
The genetic relationship among the CP C. freundii isolates was eluci-
dated by PFGE after total chromosomal DNA digestion with XbaI.15
The genetic environment of blaVIM-1 was studied using PCR mapping
and subsequent sequencing of the variable region of the class 1 integron;
the genetic environment of the blaOXA-48 gene was determined by PCR as
previously described.16
All the sequences obtained were compared with those available in
GenBank (GenBank accession numbers KC354801.1, EF093146, FJ627181,
GU086225.1 and FN396876).
Results and discussion
During the 3 year period of the study, 119 isolates of Citrobacter
spp. suspected of being carbapenemase producers according to
the EUCAST screening cut-off values for CPE10 were analysed.
Sixty-three of them (52.9%) produced carbapenemases (1.5% of
the 4129 CPE identified in the reference laboratory during the
same period of time). An increase in the CP Citrobacter spp. isolates
was observed: 1.3% in 2013 (10 out of 775), 1.7% in 2014 (25 out
of 1431) and 1.5% in 2015 (28 out of 1923). The 63 CP Citrobacter
spp. came from 27 Spanish hospitals located in 14 different prov-
inces. Fifty-seven (90.5%) of them were C. freundii, four (6.3%)
were Citrobacter koseri, one (1.6%) was Citrobacter amalonaticus
and one (1.6%) was Citrobacter braakii. Thirty-two (50.8%) pro-
duced clinical infections as follows: 19 (59.4%) urinary tract infec-
tions, 8 (25%) wound infections, 1 (3.1%) bacteraemia and
4 (12.5%) other infections. The remaining 31 (49.2%) isolates were
obtained from rectal samples.
Of the 63 CP Citrobacter spp., 37 (58.7%) produced VIM-1, 20
(31.7%) produced OXA-48, 12 (19%) produced KPC-2, 2 (3.2%)
produced NDM-1 and 1 (1.6%) produced VIM-2; 9 C. freundii co-
produced VIM-1 plus OXA-48. The modified Hodge test and the
Carba NP test yielded positive results for all the 63 CP isolates.
Fourteen (22.2%) CP Citrobacter spp. also produced ESBLs as
follows: 8 (57.1%) produced CTX-M-9 plus SHV-12 (7 of them also
producing VIM-1 plus OXA-48 and 1 producing VIM-1), 2 (14.3%)
produced CTX-M-9 (1 of them also producing VIM-1 plus OXA-48
and 1 producing OXA-48), 2 (14.3%) produced SHV-12 (1 of them
also producing OXA-48 and 1 producing VIM-1) and 2 (14.3%) pro-
duced CTX-M-15 (both also producing NDM-1). Interestingly, of the
four CP C. koseri, three of them were OXA-48 producers without
ESBL production and one co-produced NDM-1 and CTX-M-15. The
remaining two non-C. freundii isolates (one C. amalonaticus and
one C. braakii) produced VIM-1, but not ESBLs.
Antibiotic susceptibility data are displayed in Table 1. The OXA-
48-producing isolates were more susceptible to ciprofloxacin
(63.6%) and tobramycin (63.6%) than the isolates producing VIM-
1 (32.1% and 0%, respectively) and KPC-2 (0% and 33%, respect-
ively), although without statistical significance. Three isolates
(4.8%) were resistant to colistin by the commercial microdilution
commercial method used, but susceptible by the in-house micro-
dilution method recommended by EUCAST (http://www.eucast.
org/ast_of_bacteria/warnings/, last accessed April 2017); by PCR,
all three isolates were negative for mcr-1.
Of the 63 CP Citrobacter spp., 37 (58.7%) were susceptible to imi-
penem, 33 (52.4%) were susceptible to meropenem, 25 (39.7%)
Table 1. Antibiotic susceptibility of 63 CP Citrobacter spp. isolates as











Colistina 2 2 2 to2 100
Fosfomycin 32 32 32–64 93.7
Tigecycline 1 1 1–2 92.1
Amikacin 8 .32 8 to .32 71.4
Imipenem 2 .8 1 to .8 58.7
Meropenem 2 .8 1 to .8 52.4
Gentamicin 8 .8 2 to .8 42.9
Doripenem 2 .4 1 to .4 39.7
Co-trimoxazole .4 .4 2 to .4 33.3
Ciprofloxacin .2 .2 0.5 to .2 24.4
Tobramycin .8 .8 2 to .8 20.6
Ertapenem .1 .1 0.5 to .1 14.3
aThree isolates were resistant to colistin by a commercial microdilution
method, but were susceptible by the in-house microdilution method rec-
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were susceptible to doripenem and 9 (14.3%) were susceptible to
ertapenem (Table 1). These data suggest that ertapenem has the
highest sensitivity for the detection of CP Citrobacter spp. and imi-
penem the lowest, although specificity could not be determined.
However, susceptibility to carbapenems varied in relation to the car-
bapenemase types as follows: ertapenem susceptibility was 0% in
isolates producing OXA-48, 0% in OXA-48/VIM-1 producers, 16.7%
in KPC-2 producers and 25% in VIM-1 producers, while imipenem
susceptibility was 91%, 77.8%, 33.3% and 64.3%, respectively.
Interestingly, 8 (12.7%) of the 63 CP Citrobacter spp. isolates (6
of them producing VIM-1 and 2 producing KPC-2) were susceptible
to the four carbapenems tested according to EUCAST clinical
breakpoints,11 but they were suspected of being CP by the screen-
ing cut-off values recommended by EUCAST.10 According to CLSI
breakpoints,13 four of these eight isolates had an intermediate sus-
ceptibility to imipenem (MIC"2 mg/L), but were susceptible to the
other three carbapenems.
PFGE analysis revealed a high degree of genetic diversity be-
cause 44 different PFGE patterns were obtained from the 53 CP
C. freundii analysed. However, four well-defined clusters were de-
tected with a genetic linkage 84% (Figure 1). Cluster 1 (C1)
included nine VIM-1-producing C. freundii (eight of them also co-
producing OXA-48) isolated from a single hospital (East Spanish
area); all nine isolates also co-produced ESBLs (eight CTX-M-9 plus
SHV-12 and one CTX-M-9). Cluster 2 contained five VIM-1-
producing C. freundii isolated from three different hospitals located
in three neighbouring provinces, two of them very close together.
Cluster 3 consisted of five KPC-2-producing C. freundii isolated
from two hospitals of the same province in the central Spanish
area. Cluster 4 included four VIM-1-producing C. freundii isolated
from the same hospital in the central Spanish area. These results
point to a clonal dissemination of CP C. freundii within the same
hospital or between different hospitals, but also to a polyclonal dis-
semination since 30 of the CP isolates had non-related PFGE
patterns.
Interestingly, the nine C1 C. freundii isolates were collected
from faecal carriers admitted to the onco-haematology unit of a
university hospital. In the same hospital, during 2013–15, a total of
54 patients had rectal cultures positive for C. freundii co-producing
VIM-1 plus OXA-48 although no clinical infections caused by this
pathogen were observed; the 9 C1 isolates included in the study
constituted a representative sample of the 54 mentioned isolates.
The first identified carrier was a 60-year-old male diagnosed with
AML transferred from another Spanish hospital in October 2013;
this patient had a rectal culture positive for C. freundii producing
VIM-1 plus OXA-48 in November 2013.
Because cluster C1 contained the highest number of CP isolates
also producing two different types of carbapenemases, the genetic
environments of blaVIM-1 and blaOXA-48 were studied in two repre-
sentative C1 isolates. In the two isolates, VIM-1 was located in a
class 1 integron containing five resistance genes (intI–blaVIM-1–
aacA4–dfrB1–aadA1–catB2–qacED1/sul1). Also in the two isolates,
upstream of blaOXA-48, IS1999 was disrupted by the IS1R element,
but downstream of blaOXA-48 this gene was flanked by IS1999 with-
out the IS1R element, indicating the presence of a Tn1999.2.16
OXA-48 and VIM-1 are the most frequent carbapenemases de-
tected in Spain and K. pneumoniae, Enterobacter cloacae and
E. coli are the most affected species.3,4,14 However, very little infor-
mation is available about CP C. freundii.5,7,8 In addition, while some
studies have described the co-production of two carbapenemases
such as NDM-1 plus VIM-1 in C. freundii, K. pneumoniae and E. cloa-
cae17,18 or KPC-2 plus VIM-2 in K. pneumoniae,19 very few studies
have reported the co-production of VIM-1 plus OXA-4817,20 and
none of them in C. freundii. We detected a moderate increase in CP
Citrobacter spp. in Spain between 2013 and 2015; in addition, our
data revealed several remarkable findings: (i) clonal and polyclonal
spread of CP C. freundii across different geographical areas and
hospitals; (ii) carriage of five different carbapenemase types by
four species of Citrobacter spp., especially C. freundii; (iii) detection
of C. freundii co-producing OXA-48 plus VIM in carriers admitted to
an onco-haematology hospital unit; and (iv) detection of carbape-
nemases in carbapenem-susceptible isolates by EUCAST clinical
breakpoints, a finding that could have important clinical and epi-
demiological consequences. In our opinion, all these findings are
of clinical, microbiological and epidemiological interest and de-
serve active surveillance.
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Esteban Aznar (Laboratorio BrSalud, San Sebastián de los Reyes, Madrid),
Emilia Cercenado (Hospital General Universitario Gregorio Mara~nón,
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Déu Fundación Althaia, Manresa, Barcelona), Luis Torroba (Complejo
Hospitalario de Navarra, Navarra), José Luis Hernández Almaraz
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